Hasil Pencarian - Jennifer Soung

  • Menampilkan 1 - 5 hasil dari 5
Perbaiki Hasil
  1. 1
    Secukinumab Provides Rapid Relief From Itching and Pain in Patients with Moderate-to-Severe Psoriasis: Patient Symptom Diary Data from Two Phase 3, Randomized, Placebo-controlled Clinical Trials

    Secukinumab Provides Rapid Relief From Itching and Pain in Patients with Moderate-to-Severe Psoriasis: Patient Symptom Diary Data from Two Phase 3, Randomized, Placebo-controlled C... oleh Gil Yosipovitch, Jennifer Soung, Jonathan Weiss, Elisa Muscianisi, Xiangyi Meng, Isabelle Gilloteau, Boni E. Elewski

    Diterbitkan 2019-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials

    Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials oleh Jennifer Soung, Sonja Ständer, Jan Gutermuth, Ignasi Pau-Charles, Zach Dawson, Fan Emily Yang, Luna Sun, Evangeline Pierce, Hany Elmaraghy, Linda Stein-Gold

    Diterbitkan 2024-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q)

    Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q)... oleh Jennifer Soung, Jennifer C. Cather, Melinda Gooderham, Caitriona Ryan, Najwa Somani, Meghan Feely, Kyoungah See, Russel Burge, Mohamed Elrayes, Gaia Gallo, April W. Armstrong

    Diterbitkan 2023-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis

    The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis oleh Jennifer Soung, Vivian Laquer, Joseph F. Merola, Angela Moore, Hany Elmaraghy, Chaoran Hu, Maria Lucia Buziqui Piruzeli, Evangeline Pierce, Esther Garcia Gil, Abel D. Jarell

    Diterbitkan 2024-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study

    Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study oleh Amy S. Paller, Carsten Flohr, Lawrence F. Eichenfield, Alan D. Irvine, Jamie Weisman, Jennifer Soung, Ana Pinto Correia, Chitra R. Natalie, Claudia Rodriguez Capriles, Evangeline Pierce, Sarah Reifeis, Renata Gontijo Lima, Clara Armengol Tubau, Vivian Laquer, Stephan Weidinger

    Diterbitkan 2023-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: